The new site allows KGK to offer faster recruitment timelines, and it will broaden the KGK patient database to Orlando’s population of 2.1 million. Final announcements outlining site capabilities will be released shortly after the SupplySide West show.
KGK Synergize Inc. partnered with Alan Novotny, former CEO of TissueNet, to oversee the KGK U.S. site. Novotny has more than 20 years of experience with starting, building and managing multifaceted technology companies in biotech and health care related industries.
“I am thrilled about the opening of KGK U.S.," Novotny, said. “At KGK U.S., our clients can expect timelines and efficiency that is unmatched regarding clinical trials. This new site will help establish KGK as a worldwide leader in clinical trial research."
Earlier this year, KGK formed a new company, GMP Auditing Partners, a consulting firm to help manufacturing and ingredient suppliers solve GMP (good manufacturing practice) compliance problems, provide regulatory guidance and develop best business practices.